What’s Wrong With The CBD Category?Posted by On


By John McDonagh, CEO of NextEvo Naturals 

The CBD industry has rapidly increased market interest and public awareness quickly. In just a few short years, CBD products have captured global attention, including the US Food and Drug Administration, with the clearance of CBD-derived medicines like Epidiolex.

Such a rapid rise could lead some to assume that the marketplace has finished its nascency phase. But as lingering issues remain, it is clear that the industry has several pressing issues to address before reaching a significant maturation point.

Overall, the market needs more clarity and consistency to combat long-running issues, like mislabeling, that continue to hinder public trust and interest. The problems continue to dent the market’s momentum, but progress is incrementally improving the landscape. Despite the hurdles, the future appears bright for CBD operators and consumers alike; however, it is a cautionary tale.

One of the most effective ways brands can right the wrongs of the CBD category is by producing high-quality, consistent products. In doing so, operators can establish trust with their buyers and educate the public along the way. 

Addressing Absorption

Misconceptions begin right away with the CBD product category. Starting with tinctures, the highest selling form on the market today, many assume that CBD is linked hand in hand with oil. Some even call the category CBD oil. That, however, is incorrect. CBD, due its lipophilic nature, can be easily dissolved in…

Original Author Link click here to read complete story..

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.